Breast Cancer Diagnostics Market - 2040

June 2025 | 200 pages | ID: B4999EA4594EEN
DataM Intelligence

Abstracts

The Breast Cancer Diagnostics Market was valued at 3 million in 2040 and is anticipated to reach by , at a CAGR of xx% from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Breast Cancer Diagnostics Market.

This report delivers a comprehensive overview of the Breast Cancer Diagnostics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Breast Cancer Diagnostics Market. The Breast Cancer Diagnostics Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2040–.

Breast Cancer Diagnostics Market Scope:

By Cancer Type

• Invasive lobular breast cancer
• Ductal carcinoma in situ (DCIS)
• Triple-negative breast cancer
• Inflammatory breast cancer
• Others

By Test Type

• Clinical Breast Exam
• Imaging Tests
• Blood Tests
• Biopsies
• Others

By Spread

• Local
• Regional
• Distant

By Stage

• Stage I
• Stage II
• Stage III
• Stage IV

By End User

• Hospitals and Clinics
• Cancer Diagnostic Centers
• Cancer Research Institutes
• Medical Research Centers and Institutes
• Ambulatory Surgical Centers
• Others

Key Players

• Siemens Healthineers AG
• Kheiron Medical Technologies
• Bio-Rad Laboratories
• Hologic, Inc.
• Quest Diagnostics Incorporated
• FUJIFILM Holdings Corporation
• GE Healthcare
• Illumina, Inc.
• Metaltronica SpA
• Carestream Health

Major Highlights

This report delivers a comprehensive overview of the Breast Cancer Diagnostics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Breast Cancer Diagnostics Market. The Breast Cancer Diagnostics Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2040–.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

• Increase Your Customer Base by 3X using our Partner Identification tool
• Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
• Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
• Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

3.1. Snippet by Cancer Type
3.2. Snippet by Test Type
3.3. Snippet by Spread
3.4. Snippet by Stage
3.5. Snippet by End User
3.6. Snippet by Region

4. DYNAMICS

4.1. Impacting Factors
  4.1.1. Drivers
    4.1.1.1. Advancements in Diagnostic Technologies
    4.1.1.2. XX
  4.1.2. Restraints
    4.1.2.1. False Positive Results
  4.1.3. Opportunity
  4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Epidemiology
5.6. Number of Breast Cancer Tests Conducted in US, EU5, Japan, China and India 2022-2030
5.7. DMI Opinion

6. COVID-19 ANALYSIS

6.1. Analysis of COVID-19
  6.1.1. Scenario Before COVID
  6.1.2. Scenario During COVID
  6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. BY CANCER TYPE

7.1. Introduction
  7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  7.1.2. Market Attractiveness Index, By Cancer Type
7.2. Invasive lobular breast cancer*
  7.2.1. Introduction
  7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Ductal carcinoma in situ (DCIS)
7.4. Triple-negative breast cancer
7.5. Inflammatory breast cancer
7.6. Others

8. BY TEST TYPE

8.1. Introduction
  8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  8.1.2. Market Attractiveness Index, By Test Type
8.2. Clinical Breast Exam*
  8.2.1. Introduction
  8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Imaging Tests
  8.3.1. MRI
  8.3.2. Ultrasound
  8.3.3. PET
  8.3.4. Others
8.4. Blood Tests
8.5. Biopsies
  8.5.1. Excisional biopsy
  8.5.2. Incisional biopsy
  8.5.3. Core biopsy
  8.5.4. Fine-needle aspiration (FNA) biopsy
  8.5.5. Others
8.6. Others

9. BY SPREAD

9.1. Introduction
  9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spread
  9.1.2. Market Attractiveness Index, By Spread
9.2. Local*
  9.2.1. Introduction
  9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Regional
9.4. Distant

10. BY STAGE

10.1. Introduction
  10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
  10.1.2. Market Attractiveness Index, By Stage
10.2. Stage I*
  10.2.1. Introduction
  10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Stage II
10.4. Stage III
10.5. Stage IV

11. BY END USER

11.1. Introduction
  11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  11.1.2. Market Attractiveness Index, By End User
11.2. Hospitals and Clinics*
  11.2.1. Introduction
  11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Cancer Diagnostic Centers
11.4. Cancer Research Institutes
11.5. Medical Research Centers and Institutes
11.6. Ambulatory Surgical Centers
11.7. Others

12. BY REGION

12.1. Introduction
  12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  12.1.2. Market Attractiveness Index, By Region
12.2. North America
  12.2.1. Introduction
  12.2.2. Key Region-Specific Dynamics
  12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spread
  12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
  12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    12.2.8.1. U.S.
    12.2.8.2. Canada
    12.2.8.3. Mexico
12.3. Europe
  12.3.1. Introduction
  12.3.2. Key Region-Specific Dynamics
  12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spread
  12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
  12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  12.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    12.3.8.1. Germany
    12.3.8.2. UK
    12.3.8.3. France
    12.3.8.4. Italy
    12.3.8.5. Spain
    12.3.8.6. Rest of Europe
12.4. South America
  12.4.1. Introduction
  12.4.2. Key Region-Specific Dynamics
  12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spread
  12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
  12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  12.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    12.4.8.1. Brazil
    12.4.8.2. Argentina
    12.4.8.3. Rest of South America
12.5. Asia-Pacific
  12.5.1. Introduction
  12.5.2. Key Region-Specific Dynamics
  12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spread
  12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
  12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  12.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    12.5.8.1. China
    12.5.8.2. India
    12.5.8.3. Japan
    12.5.8.4. Australia
    12.5.8.5. Rest of Asia-Pacific
12.6. Middle East and Africa
  12.6.1. Introduction
  12.6.2. Key Region-Specific Dynamics
  12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spread
  12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
  12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

13. COMPETITIVE LANDSCAPE

13.1. Competitive Scenario
13.2. Market Positioning/Share Analysis
13.3. Mergers and Acquisitions Analysis

14. COMPANY PROFILES

14.1. Siemens Healthineers AG
  14.1.1. Company Overview
  14.1.2. Product Type Portfolio and Description
  14.1.3. Financial Overview
  14.1.4. Key Developments
14.2. Kheiron Medical Technologies
14.3. Bio-Rad Laboratories
14.4. Hologic, Inc.
14.5. Quest Diagnostics Incorporated
14.6. FUJIFILM Holdings Corporation
14.7. GE Healthcare
14.8. Illumina, Inc.
14.9. Metaltronica SpA
14.10. Carestream Health (*LIST NOT EXHAUSTIVE)

15. APPENDIX

15.1. About Us and Services
15.2. Contact Us